The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
- PMID: 8210301
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
Abstract
The British Isles Lupus Assessment Group (BILAG) index is a computerized index for measuring clinical disease activity in systemic lupus erythematosus (SLE), which was developed according to the principle of the physician's 'intention to treat'. The index allocates separate alphabetic scores to each of eight organ-based systems; a total score is not calculated. This study demonstrated good between-rater reliability for the BILAG index for each organ-based system. There was no evidence of bias between observers. The BILAG index had good overall sensitivity (87%) and specificity (99%) when compared with the 'gold standard' criterion (starting or increasing disease-modifying therapy). There were high positive predictive values overall (80%), and for each organ-based system, with the exception of the neurological system.
Similar articles
-
Definition and treatment of lupus flares measured by the BILAG index.Rheumatology (Oxford). 2003 Nov;42(11):1372-9. doi: 10.1093/rheumatology/keg382. Epub 2003 Jun 16. Rheumatology (Oxford). 2003. PMID: 12810926
-
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.Rheumatology (Oxford). 2005 Jul;44(7):902-6. doi: 10.1093/rheumatology/keh624. Epub 2005 Apr 6. Rheumatology (Oxford). 2005. PMID: 15814577
-
Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.J Rheumatol. 2000 Mar;27(3):664-70. J Rheumatol. 2000. PMID: 10743805
-
[Evaluation of the clinical activity of systemic lupus erythematosus].Ann Med Interne (Paris). 1990;141(3):261-4. Ann Med Interne (Paris). 1990. PMID: 2195948 Review. French.
-
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.Best Pract Res Clin Rheumatol. 2005 Oct;19(5):685-708. doi: 10.1016/j.berh.2005.03.010. Best Pract Res Clin Rheumatol. 2005. PMID: 16150398 Review.
Cited by
-
Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.Mod Rheumatol. 2016;26(1):80-6. doi: 10.3109/14397595.2015.1060665. Epub 2015 Aug 19. Mod Rheumatol. 2016. PMID: 26054418 Free PMC article. Clinical Trial.
-
Whole-body MRI for full assessment and characterization of diffuse inflammatory myopathy.Acta Radiol Open. 2016 Sep 21;5(9):2058460116668216. doi: 10.1177/2058460116668216. eCollection 2016 Sep. Acta Radiol Open. 2016. PMID: 27708860 Free PMC article.
-
Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative.Eur J Rheumatol. 2016 Mar;3(1):13-19. doi: 10.5152/eurjrheum.2015.0048. Epub 2016 Jan 29. Eur J Rheumatol. 2016. PMID: 27708963 Free PMC article.
-
Changes in apoptotic gene expression in lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients compared with healthy lymphocytes.J Clin Immunol. 2010 Sep;30(5):649-58. doi: 10.1007/s10875-010-9429-y. Epub 2010 Jun 9. J Clin Immunol. 2010. PMID: 20532967
-
Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.Clin Exp Immunol. 2005 Jul;141(1):165-73. doi: 10.1111/j.1365-2249.2005.02822.x. Clin Exp Immunol. 2005. PMID: 15958083 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical